Latest PDE5 inhibitors Stories
Regenerect for men is a new revolutionary breakthrough product that enhances and supports healthy sexual activity without the extremely harsh side effects.
MEMPHIS, Tenn., April 1, 2011 /PRNewswire/ -- Rxbuys.com is always working on the quality and range of services offered, giving its new and existing customers new options and possibilities every time they come back.
MOUNTAIN VIEW, Calif., March 29, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 10th Annual Needham Healthcare Conference.
Sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, has another possible useâ€”helping children and young adults with congenital heart disease to better tolerate exercise.
PHILADELPHIA, March 10, 2011 /PRNewswire-USNewswire/ -- Sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, has another possible use -- helping children and young adults with congenital heart disease to better tolerate exercise.
LONG ISLAND CITY, N.Y., Jan. 20, 2011 /PRNewswire/ -- Whenever someone needs high-quality drugs for less money, they are sure to go online to place their order. However, because of the large choice of pharmacies, it may not be easy to make the right decision.
SADDLE BROOK, N.J., Jan. 6, 2011 /PRNewswire/ -- The FDA's nod to a new testosterone gel for men will expand the options they have to address the problems of sexual dysfunction. "So where does this leave women?" asks Rachel Braun Scherl, president of Semprae Laboratories, Inc.
MOUNTAIN VIEW, Calif., Jan. 5, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 29th Annual JP Morgan Healthcare Conference. The VIVUS presentation will take place at the Westin St.
Product marketed for sexual enhancement contains potentially dangerous ingredient SILVER SPRING, Md., Dec. 10, 2010 /PRNewswire-USNewswire/ -- The U.S.
MOUNTAIN VIEW, Calif., Dec. 6, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED).
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.